China’s SIMM, French Drugmaker Servier To Collaborate On Anti-Tumor Medicine R&D
This article was originally published in PharmAsia News
Shanghai Institute of Materia Medica (SIMM) and French pharmaceutical company Servier Laboratories signed an agreement on the R&D of targeted antitumor drug candidate lucitanib.
You may also be interested in...
News of 5AM's two latest venture funds follows the launch of Longevity Vision Fund as well as LA BioMed's and RUNLABS’ announcements that they will open new incubators in 2019. Also, Passage Bio launches with $115.5m, but the largest recent VC deal was HaiHe's $146.6m financing.
Artificial intelligence model’s comments signal the likely start of computer-generated comments to the US FDA’s public notices.
Pink Sheet Podcast: US FDA Loses Gene Therapy Expert, Humira Biosimilars Launch, FDA Allows In-Person Meetings
Pink Sheet reporters and editors consider the impact of FDA Office of Tissues and Advanced Therapies Director Wilson Bryan’s retirement, the launch of Humira biosimilars and its effect on the biologic market, as well as the FDA moving to hybrid meetings with sponsors.